BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Reference Laboratories (BRLI) Reports 26% increase in Net Income, 22% increase in Net Revenue, 20% increase in Patient Count


8/25/2011 10:36:11 AM

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $148,029, the best ever quarter in terms of revenues in corporate history and an increase of 22% over the $121,719 recorded in the third quarter, fiscal year 2010. Net income after taxes in Q3FY11 was $10,081 resulting in fully diluted earnings per share (EPS) of $.36, up 26% and 24% respectively from the prior fiscal year third quarter net income after taxes of $8,013 and EPS of $.29. Gross profit on revenues for the current quarter was $73,432 resulting in a margin for gross profit on revenues of 50%, versus the $61,630, and 51%, reported for the prior fiscal year third quarter. Revenue per patient for the third quarter of the current fiscal year was $84.20, an increase of 2% over the $82.70 reported for the same quarter of the prior fiscal year. The number of patients served increased 20% to 1,745 in the current quarter from the prior year third quarter total of 1,460. Esoteric business for the Company was 60% of revenues for the third quarter of the current fiscal year. The Company further noted that Days Sales Outstanding (DSO) were 92 days compared to the prior fiscal year same period when the DSO were 94 days.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES